According to the American Lung Association, the national five-year lung cancer survival rate is about 29.7 percent. The ...

March 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb's combination treatment ...

Amini: This varies quite a bit by stage — operable vs. nonoperable — and patients’ performance status and preference. Additionally, more relevant to medical oncology but equally, if not more, ...

Amini: The systemic landscape is constantly changing and is very exciting. It will only become more complicated for our ...

We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus ...

Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 ---- Interim systemic lung cancer ...

On Wednesday, March 25, Columbus resident and lung cancer survivor, Nancy Vandespool, will meet with her members of Congress for the American Lung Association’s 11th annual LUNG FORCE Advocacy Day in ...

Retrospective, single-center design and limited power render findings hypothesis-generating, supporting prospective ...

Pixelgen's PNA delivers nanoscale spatial analysis of immune cell proteins at scale, as part of the company's Pixelgen Proxiome Kit. The technology is used by researchers looking for new avenues for ...

A Diaceutics report looks at when in the diagnosis, testing, and treatment process NSCLC patients lose out on access to precision medicine.

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with ...

Racial disparities persist in receipt of curative treatment for early-stage non-small cell lung cancer (NSCLC), according to a study published online March 2 in JAMA Network Open. Olivia F. Lynch, MD, ...